ATRA Stock Analysis: Buy, Sell, or Hold?
ATRA - Atara Biotherapeutics, Inc
$9.43
-0.27 (-2.74%)
▼
5d:
+12.85%
30d:
+19.42%
90d:
-3.74%
WAIT
LOW Confidence
Analysis Updated: Aug 21, 2026 12:00 AM ET
Earnings: Aug 10, 2026
0d
Get Alerted When ATRA Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: ATRA shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: ATRA shows conflicting indicators. Wait for confirmation before entering.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$23.02
Based on 7.0% avg growth
INTRINSIC VALUE TODAY
$14.29
34.0% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 14.8x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: ATRA is currently trading at $9.43, which is considered extended relative to its 30-day fair value range of $8.04 to $9.07. From a valuation perspective, the stock is trading at a discount (Forward PE: 8.7) compared to its historical average (14.8). Remarkably, the market is currently pricing in an annual earnings decline of 16.1% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, ATRA is in a strong uptrend. Immediate support is located at $7.73, while resistance sits at $9.89.
Market Sentiment: ATRA scores 23/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $13.67 (+40.9%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, ATRA is in a strong uptrend. Immediate support is located at $7.73, while resistance sits at $9.89.
Market Sentiment: ATRA scores 23/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $13.67 (+40.9%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$8.04 -
$9.07
Company Quality Score
41/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
28.6%
All Signals
- BEARISH: Price extended above range
- BEARISH: Weak technical setup (23/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 40.9% below Wall St target ($13.67)
- WARNING: Composite score 41/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$8.04 -
$9.07
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$7.73
Resistance Level
$9.89
Current Trend
Strong Uptrend
Technical data as of
Aug 21, 2026
Fundamental Context
Forward P/E (Next Year Est.)
8.74
Wall Street Target
$13.67
(+40.9%)
Revenue Growth (YoY)
-96.4%
Profit Margin
-269.4%
Valuation Discount vs History
-16.1% cheaper
PE vs Historical
8.7 vs 14.8
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-16.1%
(market-implied from PE analysis)
1-Year Target
$8.73
(-10%)
2-Year Target
$7.86
(-19%)
3-Year Target
$7.07
(-27%)
3-Yr Target (if PE normalizes)
(PE: 9→15)
$11.98
(+24%)
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 8.7 to 14.8
Stabilization Target:
$16.43
(+69.4%)
PE Expansion Potential:
+69.4%
Share & Embed Analysis
Last updated: August 24, 2026 12:55 PM ET
Data refreshes hourly during market hours. Next update: 1:55 PM
Data refreshes hourly during market hours. Next update: 1:55 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ATRA showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
CYTK
Cytokinetics Inc |
STRONG BUY
21 analysts |
$110 | 66 BUY |
|
INSM
Insmed Inc |
STRONG BUY
21 analysts |
$200 | 41 HOLD |
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$433 | 27 SELL |
|
CRSP
Crispr Therapeutics AG |
BUY
28 analysts |
$88 | 41 HOLD |
|
BHVN
Biohaven Ltd. |
STRONG BUY
16 analysts |
$23 | 49 HOLD |
